Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data
Headache: The Journal of Head and Face Pain · 2026-05 · 66 (5) · 1128-1147
DOI: 10.1111/head.70081 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 15.03.2026. Verfasst von Martina Giacon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Product Surveillance, Postmarketing, Migraine Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in a broader population. Therefore, this study aims to systematically review and synthesize findings from published pharmacovigilance studies that analyze potential safety signals for CGRP inhibitors using major international databases, including the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), the World Health Organization's (WHO's) VigiBase, and EudraVigilance, in order to establish a comprehensive real‐world safety profile to guide clinical practice.
Methods
A systematic search was conducted in major electronic databases for studies published up to September 2025. Study selection, data extraction, and quality assessment were performed by two independent researchers. We included original research articles analyzing FAERS, VigiBase, or EudraVigilance for AEs associated with erenumab, galcanezumab, fremanezumab, eptinezumab, rimegepant, ubrogepant, atogepant, or zavegepant. Data on key signals of disproportionate reporting (SDRs) and quantitative measures of disproportionality were extracted and synthesized thematically.
Results
The search identified 30 eligible studies. For mAbs, consistent SDRs included injection site reactions, alopecia (e.g., fremanezumab reporting odds ratio (ROR) ranging from 2.73 to 6.9), constipation (primarily for erenumab, RORs ranging from 4.92 to 17.94), and a range of cardiovascular events. For gepants, common SDRs included nausea and fatigue or somnolence, with highly specific SDRs for severe constipation for atogepant (ROR 025 = 19.99) and dysgeusia for zavegepant (ROR 025 = 212.07), linked to its nasal administration. A critical divergence was observed for rare but serious cerebrovascular events: SDRs for reversible cerebral vasoconstriction syndrome (RCVS [erenumab ROR 9.43, 95% confidence interval {CI} 4.5–19.8]) and cervical artery dissection (CeAD [galcanezumab ROR 14.0, 95% CI 6.22–31.4]) were associated with certain mAbs. Conversely, no such SDRs have been detected for gepants to date, although this distinction requires confirmation as real‐world exposure increases. However, a class‐level SDR for cerebrovascular diseases as a whole was identified for CGRP inhibitors as a group (ROR 1.22, 95% CI 1.12–1.33). Also notable were shared SDRs for Raynaud's phenomenon and alopecia across both subclasses. Finally, concerning safety in pregnancy, the data are complex: while comprehensive class‐level analyses did not identify a disproportionality signal compared to triptans, some analyses of individual drugs have identified reporting patterns that warrant cautious interpretation, underscoring the need for further dedicated pharmacovigilance studies to fully clarify the safety profile in this population.
Conclusions
This systematic review confirms that CGRP inhibitors have a manageable yet complex safety profile. It distinguishes rare, serious cerebrovascular events (RCVS, CeAD) associated with some mAbs but not with gepants, as well as shared adverse effects such as Raynaud's phenomenon and alopecia. Significant heterogeneity in safety profiles—from erenumab's pronounced constipation SDR to zavegepant's unique dysgeusia—challenges the view of CGRP inhibitors as a monolithic category. These findings provide a clear rationale for personalized risk assessment, enabling clinicians to tailor treatment to individual patient profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy.
ORCID-Profile: Salvatore Terrazzino
Zitieren
APA
Giacon, M., & Terrazzino, S. (2026). Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. Headache: The Journal of Head and Face Pain, 66(5), 1128-1147. https://doi.org/10.1111/head.70081
Vancouver
Giacon M, Terrazzino S. Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. Headache: The Journal of Head and Face Pain. 2026;66(5):1128-1147. doi:10.1111/head.70081
BibTeX
@article{Giacon2026,
author = {Giacon, Martina and Terrazzino, Salvatore},
title = {Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
volume = {66},
number = {5},
pages = {1128--1147},
doi = {10.1111/head.70081}
}
EUVIMED